source
- TriGemX Bio to go public via SPAC to advance migraine drug candidateTriGemX Bio, formerly known as Kallyope, said it will become a public company by merging with a special purpose acquisition company. The transaction is aimed at raising capital and accelerating the…
- Massachusetts jury awards former MIT professor David Sabatini $6 million in defamation caseA Massachusetts jury has ordered a $6 million damages award to David Sabatini, a former professor at MIT and noted biologist. The verdict stems from a defamation lawsuit that Sabatini filed after…